Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.54 |
| ▸ | PPARG | P37231 | 7/20 | 0.54 |
| ▸ | PPARD | Q03181 | 7/20 | 0.54 |
| ▸ | PPARA | Q07869 | 7/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26302700 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL2553415 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL849975 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL1285325 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL18992918 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL7197969 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL2556960 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL3121839 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL21655426 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL7199372 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNANFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859034-B2 | Curable composition, method of preparing curable composition, cured material of curable composition, method of preparing cured material, and electronic device including cured material | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20230345749-A1 | QUANTUM DOT, METHOD OF PREPARING THE SAME, AND INK COMPOSITION, LIGHT-EMITTING DEVICE, OPTICAL MEMBER, AND APPARATUS INCLUDING THE QUANTUM DOT | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-26 | — | — | US | disclosed |
| US-11649401-B2 | Quantum dot-containing material, method of preparing the same, and optical member and apparatus including the quantum dot-containing material | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-16 | — | — | US | disclosed |
| CN-115885211-A | Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element | 日产化学株式会社 | 2023-03-31 | — | — | CN | disclosed |
| US-20230086283-A1 | CURABLE COMPOSITION, METHOD OF PREPARING CURABLE COMPOSITION, CURED MATERIAL OF CURABLE COMPOSITION, METHOD OF PREPARING CURED MATERIAL, AND ELECTRONIC DEVICE INCLUDING CURED MATERIAL | SAMSUNG DISPLAY CO LTD (KR) | 2023-03-23 | — | — | US | disclosed |
| US-11512159-B2 | Curable composition, method of preparing curable composition, cured material of curable composition, method of preparing cured material, and electronic device including cured material | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-11-29 | — | — | US | disclosed |
| CN-115380245-A | Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element | 日产化学株式会社 | 2022-11-22 | — | — | CN | disclosed |
| EP-3763801-B1 | QUANTUM DOT-CONTAINING MATERIAL, METHOD OF PREPARING THE SAME, AND OPTICAL MEMBER AND APPAPRATUS INCLUDING THE QUANTUM DOT-CONTAINING MATERIAL | SAMSUNG DISPLAY CO LTD (KR) | 2022-05-04 | — | — | EP | disclosed |
| US-20210198401-A1 | CURABLE COMPOSITION, METHOD OF PREPARING CURABLE COMPOSITION, CURED MATERIAL OF CURABLE COMPOSITION, METHOD OF PREPARING CURED MATERIAL, AND ELECTRONIC DEVICE INCLUDING CURED MATERIAL | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-07-01 | — | — | US | disclosed |
| US-20210009893-A1 | QUANTUM DOT-CONTAINING MATERIAL, METHOD OF PREPARING THE SAME, AND OPTICAL MEMBER AND APPARATUS INCLUDING THE QUANTUM DOT-CONTAINING MATERIAL | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-01-14 | — | — | US | disclosed |
| US-5981580-A | IN WHICH THE CARBOXY-TERMINUS HAS BEEN MODIFIED TO FORM VARIOUS AMIDES, ESTERS, KETONES, ALCOHOLS, ALCOHOL ESTERS AND NITRITES THEREOF, AND ARE USEFUL AS SUBSTRATES FOR N-MYRISTOYLTRANSFERASE (NMT) AND/OR ITS ACYL COENZYME | G. D. SEARLE & CO. (US) | 1999-11-09 | — | — | US | disclosed |
| WO-1999050229-A1 | FATTY ACID ANALOGS AND PRODRUGS | G.D. SEARLE & CO. (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5952377-A | SUBSTRATES FOR N-MYRISTOYLTRANSFERASE (NMT) AND/OR ITS ACYL COENZYME, AS ANTI-VIRAL AND ANTI-FUNGAL AGENTS OR PRO-DRUGS; TREATING AIDS, LENTIVIRUSES SUCH AS THE HUMAN IMMUNODEFICIENCY VIRUS | G. D. SEARLE & CO. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5929110-A | USEFUL AS SUBSTRATES FOR N-MYRISTOYLTRANSFERASE (NMT) AND/OR ITS ACYL COENZYME, AND AS ANTI-VIRAL AND ANTI-FUNGAL AGENTS OR PRO-DRUGS OF SUCH AGENTS | G. D. SEARLE & CO. (US) | 1999-07-27 | — | — | US | disclosed |
| US-5859052-A | TREATING LENTIVIRUS INFECTIONS, ESPECIALLY HUMAN IMMUNODEFICIENCY VIRUS | G. D. SEARLE & CO. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5744631-A | Fatty acid analogs and prodrugs | G.D. SEARLE & CO. (US) | 1998-04-28 | — | — | US | disclosed |
| US-5719290-A | METHYLOXYUNDECYL- OR DECYLOXYETHYL-NITRILE OR TETRAZOLE DERIVATIVES; VIRICIDES | G. D. SEARLE & CO. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5672769-A | CHEMICAL INTERMEDIATES FOR VIRICIDES, FUNGICIDES | G. D. SEARLE & CO. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5670650-A | ANTIVIRAL AND ANTIFUNGAL AGENTS | G. D. SEARLE & CO. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5599947-A | VIRICIDES, FUNGICIDES OR THEIR PRODRUGS | G. D. SEARLE & CO. (US) | 1997-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11859034-B2 | Curable composition, method of preparing curable composition, cured material of curable composition, method of preparing cured material, and electronic device including cured material | SEM1, ASH2L, CBLC | ALDH1A1 2028/4885TSHR 4763/4885LMNA 1027/4885 |
| US-11512159-B2 | Curable composition, method of preparing curable composition, cured material of curable composition, method of preparing cured material, and electronic device including cured material | SEM1, ASH2L, CBLC | ALDH1A1 2028/4885TSHR 4763/4885LMNA 1027/4885 |
| US-20210198401-A1 | CURABLE COMPOSITION, METHOD OF PREPARING CURABLE COMPOSITION, CURED MATERIAL OF CURABLE COMPOSITION, METHOD OF PREPARING CURED MATERIAL, AND ELECTRONIC DEVICE INCLUDING CURED MATERIAL | SEM1, ASH2L, CBLC | ALDH1A1 2028/4885TSHR 4763/4885LMNA 1027/4885 |
| US-20230086283-A1 | CURABLE COMPOSITION, METHOD OF PREPARING CURABLE COMPOSITION, CURED MATERIAL OF CURABLE COMPOSITION, METHOD OF PREPARING CURED MATERIAL, AND ELECTRONIC DEVICE INCLUDING CURED MATERIAL | SEM1, ASH2L, CBLC | ALDH1A1 2028/4885TSHR 4763/4885LMNA 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.